Here, we show that a panel of four NRASQ61 mutant melanoma cell lines had varying sensitivity to trametinib treatment and that the Rho/MRTF pathway was activated in the subset of NRAS mutant melanoma cell lines with high intrinsic resistance to trametinib-mediated cell growth inhibition. This evidence concerns the gene NRAS and melanoma.